Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Doxecitine + doxribtimine) by UCB for Inherited Mitochondrial Disorders: Likelihood of Approval
(Doxecitine + doxribtimine) is under clinical development by UCB and currently in Phase III for Inherited Mitochondrial Disorders. According to...